Evidence map›Paper›PMID 40298448›Full record

ArticlemBio2025

Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.

Yanping Hu, Jing Zou, Michael D Nguyen, Hope C Chang, Jason Yeung, Haiping Hao, Pei-Yong Shi, Ping Ren, Xuping Xie

Abstract readComparative Study
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanping Hu *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0009-0006-8820-7437
Jing Zou *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Michael D NguyenDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Hope C ChangDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Jason YeungDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Haiping HaoDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Ping RenDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-4022-6667
Xuping XieDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0003-0918-016X

Funding

Amon G. Carter FoundationEdith and Robert ZinnJohn S. Dunn FoundationNIAID NIH HHS HHSN272201400006CRobert J. Kleberg, Jr. and Helen C. Kleberg FoundationSealy and Smith FoundationSummerfield G. Roberts Foundation
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2.86 sublineage and its descendants (JN.1, KP.2, and KP.3) have acquired key recurrent mutations (R346T, L455S, F456L, and Q493E) and became predominant strains, following the epidemiological progression: BA.2.86→JN.1→KP.2→KP.3. However, the mechanisms driving this succession remain incompletely understood. In this study, we assessed the replication fitness of SARS-CoV-2 strains containing spike sequences from BA.2.86 and its descendants (JN.1, KP.2, and KP.3) in primary human airway epithelium cells and their sensitivity to neutralization by human sera. Our analysis revealed reduced spike cleavage in JN.1 and KP.2 virions compared to BA.2.86 and KP.3, indicating that receptor-binding domain (RBD) mutations L455S and Q493E, despite being distant from the furin cleavage site, can influence spike cleavage. JN.1, with the additional L455S mutation, replicated more slowly than BA.2.86 but was more resistant to neutralization by XBB.1.5-infection sera, suggesting that immune evasion driven by the L455S mutation is the primary factor behind the BA.2.86-to-JN.1 transition. KP.2, carrying additional R346T, L455S, and F456L mutations, showed both enhanced replication and increased resistance to neutralization by JN.1-infection sera, indicating that the combined effects of these mutations on immune evasion and viral fitness drive the JN.1-to-KP.2 shift. The latest strain, KP.3, derived from JN.1 with the L455S, F456L, and Q493E mutations, demonstrated even greater replication than KP.2 while maintaining similar neutralization sensitivity to JN.1-infection sera, suggesting that Q493E further enhances viral replication and drives the KP.2-to-KP.3 transition. These findings highlight how specific recurrent spike mutations in BA.2.86 descendants fine-tune viral replication fitness and immune evasion, promoting their emergence and dominance. IMPORTANCE: The study advances our understanding of the roles of immune evasion and replication fitness in driving the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the BA.2.86 sublineage to its descendants (JN.1, KP.2, and KP.3). Through head-to-head comparisons of the replication fitness of recombinant SARS-CoV-2 strains containing spike sequences from BA.2.86 and its descendants in primary human airway epithelium cells, alongside assessments of their neutralization sensitivity to human sera, we revealed how recurrent mutations R346T, L455S, F456L, and Q493E in the receptor-binding domain (RBD) fine-tune immune evasion and viral replication fitness, underscoring the critical need for updated countermeasures to combat newly emerged SARS-CoV-2 variants. Additionally, our analysis showed that the L455S and Q493E mutations in the RBD can influence spike cleavage, offering new insights into SARS-CoV-2 spike biology.

Indexed as

COVID-19Immune EvasionSARS-CoV-2Virus ReplicationAntibodies, NeutralizingAntibodies, ViralHumansMutationSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BA.2.86immune evasionJN.1KP.2KP.3SARS-CoV-2viral fitness

Identifiers

PMID40298448
PMCPMC12153290

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.